AQST
Aquestive Therapeutics, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -18.2% ·
share flow +10.3% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 71 | +3 | 38.90M | $161.83M | +5 | −3 |
| Q1 2026 | 71 | -4 | 39.34M | $163.45M | +7 | −11 |
| Q4 2025 | 75 | 0 | 41.69M | $269.29M | +1 | −1 |
| Q3 2025 | 16 | 0 | 21.57M | $120.55M | +1 | −1 |
| Q2 2025 | 13 | +1 | 18.15M | $60.07M | +1 | — |
| Q1 2025 | 9 | -2 | 4.86M | $14.09M | — | −2 |
| Q4 2024 | 11 | +1 | 4.40M | $15.68M | +1 | — |
| Q3 2024 | 9 | +1 | 3.11M | $15.51M | +2 | −1 |
| Q2 2024 | 8 | — | 2.58M | $6.65M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.70M | +2.8% | $4.93M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 2 | State Street Global Advisors ✦ (passive) | 1.52M | +1.2% | $4.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 459.55K | +20.4% | $1.33M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Two Sigma Investments ✦ | 372.06K | +111.5% | $1.08M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Millennium Management ✦ | 258.22K | +196.0% | $748,826 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 205.54K | +14.4% | $596,078 | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 179.03K | +41.6% | $519,202 | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | AQR Capital Management ✦ | 129.02K | +12.2% | $374,155 | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
| 9 | T. Rowe Price ✦ | 32.09K | +16.0% | $94,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Renaissance Technologies | $339,624 | was 0.0% |
| Marshall Wace | $198,275 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 174 holders, 66.03M shares, $284.02M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 25.00K sh · $120,488
Officer · 8.75K sh · $45,675
Officer, Director · 25.00K sh · $107,168
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology